间充质干细胞
癌症研究
CD44细胞
泛素连接酶
化学
细胞生物学
生物
泛素
细胞
基因
生物化学
作者
Shangbiao Li,Yanwen Chen,Youhua Xie,Hongchao Zhan,Yu Zeng,Kunlin Zeng,Li Wang,Ziling Zhan,Cuiying Li,Liqian Zhao,Xiaoxia Chen,Yujing Tan,Zhongyong Wang,Junguo Bu,Ye Song,Fan Deng,Aidong Zhou
标识
DOI:10.1002/advs.202303561
摘要
Abstract Mesenchymal glioblastoma (GBM) is highly resistant to radio‐and chemotherapy and correlates with worse survival outcomes in GBM patients; however, the underlying mechanism determining the mesenchymal phenotype remains largely unclear. Herein, it is revealed that FBXO7, a substrate‐recognition component of the SCF complex implicated in the pathogenesis of Parkinson's disease, confers mesenchymal properties and chemoresistance in GBM by controlling Rbfox2‐mediated alternative splicing. Specifically, FBXO7 ubiquitinates Rbfox2 Lys249 through K63‐linked ubiquitin chains upon arginine dimethylation at Arg341 and Arg441 by PRMT5, leading to Rbfox2 stabilization. FBXO7 controls Rbfox2‐mediated splicing of mesenchymal genes, including FoxM1, Mta1 , and Postn . FBXO7‐induced exon Va inclusion of FoxM1 promotes FoxM1 phosphorylation by MEK1 and nuclear translocation, thereby upregulates CD44, CD9, and ID1 levels, resulting in GBM stem cell self‐renewal and mesenchymal transformation. Moreover, FBXO7 is stabilized by temozolomide, and FBXO7 depletion sensitizes tumor xenografts in mice to chemotherapy. The findings demonstrate that the FBXO7‐Rbfox2 axis‐mediated splicing contributes to mesenchymal transformation and tumorigenesis, and targeting FBXO7 represents a potential strategy for GBM treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI